267 related articles for article (PubMed ID: 8307503)
1. The prognostic value of TPA and SCC in squamous cell carcinoma of the cervix.
Ngan HY; Cheng GT; Yeung WS; Wong LC; Ma HK
Gynecol Oncol; 1994 Jan; 52(1):63-8. PubMed ID: 8307503
[TBL] [Abstract][Full Text] [Related]
2. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P
Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246
[TBL] [Abstract][Full Text] [Related]
3. Application of tumor markers CEA, TPA, and SCC-Ag in patients with low-risk FIGO stage IB and IIA squamous cell carcinoma of the uterine cervix.
Juang CM; Wang PH; Yen MS; Lai CR; Ng HT; Yuan CC
Gynecol Oncol; 2000 Jan; 76(1):103-6. PubMed ID: 10620449
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of TPA versus SCC-Ag, CEA and neopterin in carcinoma of the uterine cervix.
Volgger B; Aspisirengil C; Genser-Krimbacher E; Ciresa-Koenig A; Daxenbichler G; Fuchs D; Windbichler G; Marth C
Cancer Lett; 2008 Apr; 262(2):183-9. PubMed ID: 18226853
[TBL] [Abstract][Full Text] [Related]
5. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?
Gaarenstroom KN; Kenter GG; Bonfrer JM; Korse CM; Van de Vijver MJ; Fleuren GJ; Trimbos JB
Gynecol Oncol; 2000 Apr; 77(1):164-70. PubMed ID: 10739706
[TBL] [Abstract][Full Text] [Related]
6. Squamous cell carcinoma antigen, tumor associated trypsin inhibitor and tissue polypeptide specific antigen in follow up of stage III cervical cancer.
Gitsch G; Kainz C; Joura E; Fröhlich B; Bieglmayr C; Tatra G
Anticancer Res; 1992; 12(4):1247-9. PubMed ID: 1503417
[TBL] [Abstract][Full Text] [Related]
7. Squamous cell carcinoma antigen: clinical utility in squamous cell carcinoma of the uterine cervix.
Bolli JA; Doering DL; Bosscher JR; Day TG; Rao CV; Owens K; Kelly B; Goldsmith J
Gynecol Oncol; 1994 Nov; 55(2):169-73. PubMed ID: 7959279
[TBL] [Abstract][Full Text] [Related]
8. Monitoring of serum squamous cell carcinoma antigen levels in invasive cervical cancer: is it cost-effective?
Chan YM; Ng TY; Ngan HY; Wong LC
Gynecol Oncol; 2002 Jan; 84(1):7-11. PubMed ID: 11748969
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of pretreatment squamous cell carcinoma antigen and carcinoembryonic antigen in squamous cell carcinoma of the uterine cervix.
Bae SN; Namkoong SE; Jung JK; Kim CJ; Park JS; Kim JW; Lee JM; Kim SJ
Gynecol Oncol; 1997 Mar; 64(3):418-24. PubMed ID: 9062143
[TBL] [Abstract][Full Text] [Related]
10. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature.
Gadducci A; Tana R; Cosio S; Genazzani AR
Crit Rev Oncol Hematol; 2008 Apr; 66(1):10-20. PubMed ID: 17964182
[TBL] [Abstract][Full Text] [Related]
11. [The importance of the SCC antigen in the diagnosis and follow-up of cervix carcinoma. A cooperative study of the Gynecologic Tumor Marker Group (GTMG)].
Crombach G; Würz H; Herrmann F; Kreienberg R; Möbus V; Schmidt-Rhode P; Sturm G; Caffier H; Kaesemann H
Dtsch Med Wochenschr; 1989 May; 114(18):700-5. PubMed ID: 2714197
[TBL] [Abstract][Full Text] [Related]
12. [Correlation of serum squamous cell carcinoma antigen with clinico-pathological features and prognosis of squamous cell carcinoma of uterine cervix].
Xiong Y; Liang LZ; Zheng M; Wei M; Shen Y
Zhonghua Fu Chan Ke Za Zhi; 2007 Jan; 42(1):29-33. PubMed ID: 17331418
[TBL] [Abstract][Full Text] [Related]
13. Early predicting recurrent cervical cancer with combination of tissue polypeptide specific antigen (TPS) and squamous cell carcinoma antigen (SCC).
Hung YC; Shiau YC; Chang WC; Kao CH; Lin CC
Neoplasma; 2002; 49(6):415-7. PubMed ID: 12584591
[TBL] [Abstract][Full Text] [Related]
14. The value of squamous cell carcinoma antigen in the prognostic evaluation, treatment monitoring and followup of patients with penile cancer.
Zhu Y; Ye DW; Yao XD; Zhang SL; Dai B; Zhang HL; Shen YJ
J Urol; 2008 Nov; 180(5):2019-23. PubMed ID: 18801542
[TBL] [Abstract][Full Text] [Related]
15. Squamous cell carcinoma antigen in follow-up of cervical cancer treated with radiotherapy: evaluation of cost-effectiveness.
Forni F; Ferrandina G; Deodato F; Macchia G; Morganti AG; Smaniotto D; Luzi S; D'Agostino G; Valentini V; Cellini N; Giardina B; Scambia G
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1145-9. PubMed ID: 17689030
[TBL] [Abstract][Full Text] [Related]
16. CYFRA 21-1, TPA-M, TPS, SCC-Ag and CEA in patients with squamous cell lung cancer and in chemical industry workers as a reference group.
Kulpa J; Wójcik E; Radkowski A; Kolodziejski L; Stasik Z
Anticancer Res; 2000; 20(6D):5035-40. PubMed ID: 11326663
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of pre-treatment circulating monocyte count in patients with cervical cancer: comparison with SCC-Ag level.
Lee YY; Choi CH; Sung CO; Do IG; Huh S; Song T; Kim MK; Kim HJ; Kim TJ; Lee JW; Kim BG; Bae DS
Gynecol Oncol; 2012 Jan; 124(1):92-7. PubMed ID: 22014631
[TBL] [Abstract][Full Text] [Related]
18. Cytokeratin subunit 19 measured by CYFRA 21-1 assay in follow-up of cervical cancer.
Kainz C; Sliutz G; Mustafa G; Bieglmayr C; Koelbl H; Reinthaller A; Gitsch G
Gynecol Oncol; 1995 Mar; 56(3):402-5. PubMed ID: 7535720
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of serum and immunohistochemical expression of SCC and CA19-9 in radiation therapy for cervical cancer.
Abe A; Nakano T; Morita S; Oka K
Anticancer Res; 1999; 19(1B):829-36. PubMed ID: 10216501
[TBL] [Abstract][Full Text] [Related]
20. Value of Cyfra 21-1, TPA, and SCC-Ag in predicting extracervical disease and prognosis in cervical cancer.
Gaarenstroom KN; Bonfrer JM; Korse CM; Kenter GG; Kenemans P
Anticancer Res; 1997; 17(4B):2955-8. PubMed ID: 9329574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
